NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Laser777,

Thank you for that Yescarta update.(and important for the DCVAX-L appraisal!)

Comment of Meindert Boysen, director of the centre for health technology evaluation at NICE.

http://www.irishnews.com/magazine/science/2018/08/28/news/-breakthrough-personalised-cancer-treatment-rejected-for-nhs-use-1418127/

The National Institute for Health and Care Excellence (Nice) published draft guidance stating that axicabtagene ciloleucel, also known as Yescarta, is not recommended for NHS use for patients with aggressive sub-types of non-Hodgkin lymphoma.

Quote:

“But Nice said that there is no direct data to compare it with the current standard treatment of salvage chemotherapy.
It said that cost of axicabtagene ciloleucel was also too high for it to be considered a cost-effective use of NHS resources.

The health body also considered whether the treatment should be made available to patients through the Cancer Drugs Fund, but concluded that the therapy would not be cost-effective under the scheme.

Meindert Boysen, director of the centre for health technology evaluation at Nice, said: “CAR-T is an exciting innovation in very difficult-to-treat cancers, with a promise of cure for some patients.
“We have been working with the companies involved, and with NHS England, with the aim of ensuring that patients in England are among the first to have access to these new treatments in Europe.

“Although promising, there is still much more we need to know about CAR-T, and unfortunately, in this case, we are not able to recommend axicabtagene ciloleucel for use in the NHS in England at the cost per patient set by Kite Pharma.”

Does CAR-T Therapy Have a Payment Problem?
Published: Aug 23, 2018 By Mark Terry

https://www.biospace.com/article/does-car-t-therapy-have-a-payment-problem-/